Radionuclide-(Lutetium)-Therapy-Service-Cancer-Treatment-Beacon-Hospital-Malaysia

Lutetium 177 PSMA Therapy

Lutetium-177 PSMA therapy is used to treat patients with advanced prostate cancers particularly those that have become resistant to the standard systemic treatments. Prostate cancers that have spread to other sites of the body expresses a unique substance on their cell surface known as Prostate Specific Membrane Antigen.

Lu-177 tagged together with the PSMA will specifically attach itself to cells with high expression of PSMA thus enabling the delivery of high doses of targeted radiation therapy while sparing the healthy normal tissues nearby.

Early clinical studies evaluating the safety and efficacy of Lu-177 PSMA therapy have demonstrated promising results with a significant proportion of men with advanced metastatic resistant prostate cancer, who have failed other treatment options, responding clinically to Lu177-PSMA.

The benefits of this targeted radionuclide therapy may include shrinkage of tumours, a reduction in blood PSA (Prostate Specific Antigen) level, improvement in symptoms such as pain and a general improvement in overall well-being.